Sarepta Therapeutics, Inc.
SRPT
$18.10
-$0.32-1.74%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -136.73M | 65.06M | -713.41M | -271.51M | -57.96M |
| Total Depreciation and Amortization | 44.71M | 45.14M | 44.52M | 49.72M | 41.08M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 335.66M | 291.52M | 385.37M | 363.62M | 289.98M |
| Change in Net Operating Assets | -132.63M | -226.44M | 78.04M | -386.47M | -573.86M |
| Cash from Operations | 111.01M | 175.28M | -205.48M | -244.64M | -300.75M |
| Capital Expenditure | -29.16M | -60.40M | -101.97M | -136.46M | -150.79M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 130.01M | 286.83M | 171.61M | 874.02M | 527.12M |
| Cash from Investing | 100.85M | 226.43M | 69.64M | 737.55M | 376.33M |
| Total Debt Issued | 425.00M | 250.00M | -- | -- | -- |
| Total Debt Repaid | -584.07M | -409.38M | -162.59M | -127.52M | -3.58M |
| Issuance of Common Stock | 21.76M | 23.26M | 38.70M | 42.11M | 34.65M |
| Repurchase of Common Stock | 0.00 | -25.01M | -25.01M | -25.01M | -25.01M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -19.45M | -19.45M | -19.45M | 30.29M | 45.35M |
| Cash from Financing | -156.76M | -180.57M | -168.34M | -80.15M | 51.40M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 55.10M | 221.13M | -304.18M | 412.77M | 126.98M |